Abstract
Out of 153 patients with laryngeal cancer who were treated in the past 15 years since 1988, for 56 patients with Stage III & IV, the difference of regimen, therapeutic effect and ratio of larynx which could be preserved for each period of chemoradiotherapy are veviewed. Our treatment is concurrent chemoradiotherapy in which chemotherapy and radiotherapy are performed on the same day. The contents of chemotherapy changed as follows: CDDP+PEP (around 1988-1996), CDDP+5-FU (around 1994-2001), and S-1+Nedaplatin (since 2001). The CR rate of the CDDP+PEP therapy for Stage III & IV laryngeal cancer was 38.4%. The CR rate of the CDDP+5-FU therapy was 31% and the effect which had been expected was not obtained in the progress stage.
On the other hand, the effucacy rate and CR rate of the S-1+Nedaplatin therapy were very good with 100% and 90% respectively. The ratio of larynx which could be preserved were 46% by the CDDP+PEP therapy and 44% by the CDDP+5-FU therapy, but by the S-1+Nedaplatin therapy, 90% of the larynx could be preserved and there is no case of recurrence till now. In the chemoradiotherapy to date, the high target value for larynx conservation could not be achieved. However, with the S-1+Nedaplatin therapy which is becoming the norm, there was significant improvement in the efficacy rate, the CR ratio and the rate of larynx which could be preserved.
